Urea derivatives as anticancer agents

Anti-Cancer Agents in Medicinal Chemistry

Volumn 9, Issue 4, 2009, Pages 471-480

  Li, Huan Qiu ^a   Lv, Peng Cheng ^a   Yan, Tao ^a   Zhu, Hai Liang ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Anticancer agents; Aromatic areas; Heterocyclicureas; Structure activity relationships; Thiourea; Urea derivatives

Indexed keywords

3 AMINOINDAZOLE UREA DERIVATIVE; 4 TERT BUTYL [3 (2 CHLOROETHYL)UREIDO]BENZENE; ACYLTHIOUREA DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATIC UREA DERIVATIVE; BENZOTHIAZOLE DERIVATIVE; BENZOYLUREA DERIVATIVE; CD135 ANTIGEN INHIBITOR; CHECKPOINT KINASE 1; DIARYLSULPHONYLUREA DERIVATIVE; DOXORUBICIN; HETEROCYCLIC UREA DERIVATIVE; MACROCYCLIC ARYLUREA DERIVATIVE; N (3 ACYLOXY 2 BENZYLPROPYL) N' [4 (METHYLSULFONYLAMINO)BENZYL]THIOUREA DERIVATIVE; N 92 CHLOROBENZOYL) N' [3 CHLORO 4(5 TRIFLUOROMETHYL 2 PYRIDYLOXY)PHENYL]UREA; N PHENYL N' (2 CHLOROETHYL)UREA DERIVATIVE; N [2 (3,4 DIMETHYLBENZYL) 3 PIVALOYLOXYPROPYL] N' [3 FLUORO 4 (METHYLSULFONYLAMINO)BENZYL]THIOUREA; N [4 (5 BROMO 2 PYRIMIDINYLOXY) 3 CHLOROPHENYL] N' (2 NITROBENZOYL)UREA; N [4 (5 BROMO 2 PYRIMIDINYLOXY) 3 METHYLPHENYLCARBAMOYL) N' (2 DIMETHYLAMINO)UREA; PROTEIN BCL 2; PROTEIN TYROSINE KINASE; SIRTUIN; SIRTUIN INHIBITOR; SOMATOSTATIN; THIENOPYRIMIDINE UREA DERIVATIVE; THIOUREA DERIVATIVE; UNCLASSIFIED DRUG; UREA DERIVATIVE; VASCULOTROPIN RECEPTOR 1; DRUG DERIVATIVE; SULFONYLUREA DERIVATIVE; THIOUREA; TUBULIN; UREA;

ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; COLON ADENOCARCINOMA; DNA DAMAGE; DRUG EFFICACY; FIBROSARCOMA; HUMAN; IC 50; LEUKEMIA; LIVER CELL CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PROTEIN PHOSPHORYLATION; REVIEW; STRUCTURE ACTIVITY RELATION; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INHIBITORY CONCENTRATION 50; MAP KINASE SIGNALING SYSTEM; PROTEIN-TYROSINE KINASES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONYLUREA COMPOUNDS; THIOUREA; TUBULIN; UREA;

EID: 67649774465     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871520610909040471     Document Type: Review

References (110)

1. Gnewuch, C.T.; Sosnovsky, G. A critical appraisal of the evolution of N-nitrosoureas as anticancer drugs. Chem. Rev. 1997, 97(3), 829-1013.
2. Okada, H.; Koyanagi, T.; Yamada, N. Synthesis and antitumor activities of prodrugs of benzoylphenylureas. Chem. Pharm. Bull. 1994, 42(1), 57-61.
3. Toth, J.E.; Grindey, G.B.; Ehlhardt, W.J.; Ray, J.E.; Boder, G.B.; Bewley, J.R.; Klingerman, K.K.; Gates, S.B.; Rinzel, S.M.; Schultz, R.M.; Weir, L.C.; Worzalla, J.F. Sulfonimidamide analogs of oncolytic sulfonylureas. J. Med. Chem. 1997, 40(6), 1018-1025.
4. 1-S transition and M phase by 3-Iodoacetamido benzoyl ethyl ester, a new type of tubulin ligand. Cancer Res. 2002, 62(21), 6080-6088.
5. Wang, J.C. DNA topoisomerases. Annu. Rev. Biochem. 1996, 65(4), 635-692.
6. Pommier, Y. Diversity of DNA topoisomerases I and inhibitors. Biochimie 1998, 80(3), 255-270.
7. Redinbo, M.R.; Stewart, L.; Kuhn, P.; Champoux, J.J.; Hol, W.G.J. Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science 1998, 279(5356), 1504-1513.
8. Singh, S.K.; Ruchebman, A.L.; Li, T.K.; Liu, A.; Liu, A.F.; Lavoie, E.J. Nitro and amino substitution in the D-Ring of 5-(2-Dimethylaminoethyl)-2,3-methylenedioxy-5-H-dibenzo[c,h][1, 6]naphthyridin-6-ones: effect on topoisomerase-I targeting activity and cytotoxicity. J. Med. Chem. 2003, 46(11), 2254-2257.
9. Olaharski, A.J.; Mondrala, S.T.; Eastmond, D.A. Chromosomal malsegregation and micronucleus induction in vitro by the DNA topoisomerase II inhibitor fisetin. Mutant Res. 2005, 582(1-2), 79-86.
10. Jiang, J.D.; Roboz, J.; Weisz, I.; Deng, L.; Ma, L.; Holland, J.F.; Bekesi, J.G. Synthesis, cancericidal and antimicrotubule activities of 3-(haloacetamido)-benzoylureas. Anti-Cancer Drug Des. 1998, 13(7), 735-747.
11. Easmon, J.; Purstinger, G.; Heinisch, G.; Roth, T.; Fiebig, H.H.; Holzer, W.; Jager, W.; Jenny, M.; Hofmann, J. Synthesis, cytotoxicity, and antitumor activity of copper(II) and iron(II) complexes of 4N-azabicyclo[3.2.2]nonane thiosemicarbazones derived from acyl diazines. J. Med. Chem. 2001, 44(13), 2164-2171.
12. Fujita, F.; Fujita, M.; Inaba, H.; Sugimoto, T.; Okuyama, Y.; Taguchi, T. Combination chemotherapy of HO-221, a derivative of benzoylphenylurea with various anticancer agents against human cancer xenografts in nude mice. Gan To Kagaku Ryoho 1991, 18(13), 2263-2270.
13. Morré, D.J. The antitumor sulfonylurea N-(4-methylphenylsul-fonyl)-N -(4-chlorophenyl) urea (LY181984) inhibits NADH oxidase activity of HeLa plasma membranes. Biochim. Biophys. Acta 1995, 1240(1), 11-17.
14. Skipper, H.E.; Schabel, F.M. Jr.; Wilcox, W.S. Experimental evaluation of potential anticancer agents XIII on the criteria and kinetics associated with "curability" of experimental leukemia. Cancer Chemother. Rep. 1964, 35(1), 1-111.
15. Skipper, H.E.; Schabel, F.M. Jr.; Trader, M.W.; Thomson, J.R. Experimental evaluation of potential anticancer agents VI. Anatomical distribution of leukemic cells and failure of chemotherapy. Cancer Res. 1961, 21(9), 1154-1164.
16. Moreau, E.; Fortin, S.; Desjardins, M.; Rousseau, J.L.C.; Petitclerc, E.; C.-Gaudreault, R. Optimized N-phenyl-N'-(2-chloroethyl)ureas as potential antineoplastic agents: Synthesis and growth inhibition activity. Bioorg. Med. Chem. 2005, 13(24), 6703-6712.
17. Dolan, M.E.; Fleig, M.J.; Feuerstein, B.G.; Basu, H.S.; Luk, G.D.; Casero, R.A.; Marton, L.J. Effect of 1,19-bis(ethylamino)-5,10,15-triazanonadecane on human tumor xenografts. Cancer Res. 1994, 54(17), 4698-4702.
18. Rich, Clapp. Environment and health: 4. Cancer. CMAJ 2000, 163(8), 1009-1012.
19. Weinstein, I.B. Cancer prevention: recent progress and future opportunities. Cancer Res. 1991, 51(18), 5080-5085.
20. Workman, P. Introduction: new anticancer drug design and discovery based on advances in molecular oncology. Semin Cancer Biol. 1992, 3(6), 329-333.
21. Powis, G.; Alberts, D.S. Inhibiting intracellular signalling as a strategy for cancer chemoprevention. Eur. J. Cancer 1994, 30(8), 1138-1144.
22. Lenz, G.R.; Nash, H.M.; Jindal, S. Chemical ligands, genomics and drug discovery. Drug Discov. Today 2000, 5(4), 145-156.
23. Jordan, M.A.; Wilson, L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr. Opin. Cell Biol. 1998, 10(1), 123-130.
24. Lacroix, J.; C-Gaudreault, R.; Pagé, M.; Joly, P. In vitro and in vivo activity of 1-aryl-3-(2-chloroethyl) urea derivatives as new antineoplastic agents. Anticancer Res. 1988, 8(4), 595-598.
25. Bouchon, B.; Chambon, C.; Mounetou, E.; Papon, J.; Miot-Noirault, C.; C-Gaudreault, R.C.; Madelmont, J.C.; Degoul, F. Alkylation of β-Tubulin on Glu 198 by a microtubule disrupter. Mol. Pharmacol. 2005, 68(5), 1415-1422.
26. Jordan,M.A.;Wilson, L. Microtubules as a target for anticancer drugs. Nat. Cancer Rev. 2004, 4(4), 253-265.
27. Cragg, G.M.; Newman, D.J. Marine natural products and related compounds in clinical and advanced preclinical trials. J. Nat. Prod. 2004, 67(2), 232-244.
28. Song, D.Q.; Wang, Y.; Wu, L.Z.; Yang, P.; Wang, Y.M.; Gao, L.M.; Li, Y.; Qu, J.R.; Wang, Y.H.; Li, Y.H.; Du, N.N.; Han, Y.X.; Zhang, Z.Z.; Jiang, J.D. Benzoylurea derivatives as a novel class of antimitotic agents: synthesis, anticancer activity, and structure-activity relationships. J. Med. Chem. 2008, 51(11), 3094-3103.
29. Roe, S.M.; Podromou, C.; O'Brien, R.; Ladbury, J.E.; Piper, P.W.; Pearl, L.H. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem. 1999, 42(2), 260-266.
30. Chern, J.W.; Leu, Y.L.; Wang, S.S.; Jou, R.; Lee, C.F.; Tsou, P.C.; Hsu, S.C.; Liaw, Y.C.; Lin, H.M. Synthesis and cytotoxic evaluation of substituted sulfonyl-N-hydroxyguanidine derivatives as potential antitumor agents. J. Med. Chem. 1997, 40(14), 2276-2286.
31. Jiang, J.D.; Davis, A.S.; Middleton, K.; Ling, Y.H.; Roman, P.S.; Holland, J.F.; Bekesi, J.G. 3-(Iodoacetmido)-bezoylurea: a novel cancericidal tubulin ligand that inhibits microtubule polymerization, phosphorylates bcl-2, and induces apoptosis in tumor cells. Cancer Res. 1998, 58(23), 5389-5395.
32. Li, J.N.; Song, D.Q.; Lin, Y.H.; Hu, Q.Y.; Yin, L.; Bekesi, G.; Holland, J.F.; Jiang, J.D. Inhibition of microtubule polymerization by 3-bromopropionylamino benzoylurea (JIMB01), a new cancericidal tubulin ligand. Biochem. Pharmacol. 2003, 65(10), 1691-1699.
33. Tao, Z.F.; Lin, N.H. Chk1 inhibitors for novel cancer treatment. Anticancer. Agents. Med. Chem. 2006, 6(4), 377-388.
34. Lin, N.-H.; Li, G.; Przytulinska, M. K.; Sowin, T. J.; Sullivan, G. M.; Tao, Z.-F.; Tong, Y.; Wang, L. Macrocyclic kinase inhibitors. U.S. Patent 7163939, 2007.
35. Kiselyov, A.; Konstantin, V. B.; Sergey, E. T.; Nikolay, S.; Alexandre, V. I. Recent progress in discovery and development of antimitotic agents. Anti-Cancer Agents Med. Chem. 2007, 7(2), 189-208.
36. Nakajima, T.; Masuda, H.; Okamoto, T.; Watanabe, M.; Yokoyama, K.; Yamada, N.; Tsukagoshi, S.; Taguchi, T. Antitumor effect of a benzoylphenylurea derivative HO-221. Gan To Kagaku Ryoho 1990, 17(12), 2353-2359.
37. Fujita, F.; Fujita, M.; Inaba, H.; Sugimoto, T.; Okuyama, Y.; Taguchi, T. Antitumor activity of HO-221, a derivative of benzoylphenylurea against human cancer xenografts in nude mice. Gan To Kagaku Ryoho 1991, 18(13), 2255-2261.
38. Gurulingappa, H.; Amador, M.L.; Zhao, M.; Rudek, M.A.; Hidalgo, M.; Khan, S.R. Synthesis and antitumor evaluation of benzoylphenylurea analogs. Bioorg. Med. Chem. Lett. 2004, 14(9), 2213-2216
39. Bechard, P.; Lacroix, J.; Poyet, P.; Gaudreault, R.C. Synthesis and cytotoxic activity of new alkyl[3-(2-chloroethyl)ureido] benzene derivatives. Eur. J. Med. Chem. 1994, 29(12), 963-966.
40. C.-Gaudreault, R.; Lacroix, J.; Pagé, M.; Joly, L.P. 1-Aryl-3-(2-chloroethyl) ureas: synthesis and in vitro assay as potential anticancer agents. J. Pharm. Sci. 1988, 77(2), 185-187.
41. C.-Gaudreault, R.; Alaoui-Jamali, M.A.; Batist, G.; Be chard, P.; Lacroix, J.; Poyet, P. Lack of cross-resistance to a new cytotoxic arylchloroethyl urea in various drug-resistant tumor cells. Cancer Chemother. Pharmacol. 1994, 33(6), 489-492.
42. Legault, J.; Gaulin, J.-F.; Mounetou, E.; Ritchot, N.; Lacroix, J.; Poyet, P.; C.-Gaudreault, R. Microtubule disruption induced in vivo by alkylation of β-tubulin by 1-Aryl-3- (2-Chloroethyl)ureas, a novel class of soft alkylating agents. Cancer Res. 2000, 60(4), 985-992.
43. Bouchon, B.; Chambon, C.; Mounetou, E.; Papon, J.; Miot-Noirault, E.; C.-Gaudreault, R.; Madelmont, J.-C.; Degoul, F. Alkylation of β-tubulin on Glu 198 by a microtubule disrupter. Mol. Pharmacol. 2005, 68(5), 1415-1422.
44. Mounetou, E.; Legault, J.; Lacroix, J.; C.-Gaudreault, R. Antimitotic antitumor agents: synthesis, structure activity relationships, and biological characterization of N-Aryl-N'-(2-chloroethyl)ureas as new selective alkylating agents. J. Med. Chem. 2001, 44(5), 694-702.
45. Prinz, H. Recent advances in the field of tubulin polymerization inhibitors. Expert Rev. Anticancer Ther. 2002, 2(6), 695-708.
46. Lacroix, J.; C-Gaudreault, R.; Page, M.; Joly, P. In vitro and in vivo activity of 1-aryl-3-(2-chloroethyl) urea derivatives as new antineoplastic agents. Anticancer Res. 1988, 8(4), 595-598.
47. Okada, H.; Kato, M.; Koyanagi, T.; Mizuno, K. Synthesis and antitumor activities of water-soluble benzoylphenylureas. Chem. Pharm. Bull. 1999, 47(3), 430-433.
48. Saint-Laurent, A.; Boudreau, N.; Lariviére, D.; Legault, J.; C-Gaudreault, R. C.; Auger, M. Membrane interactions of a new class of anticancer agents derived from arylchloroethylurea: a FTIR spectroscopic study. Chem. Phys. Lipids 2001, 111(2), 163-175.
49. Mounetou, E.; Legault, J.; Lacroix, J.; C-Gaudreault, R.C.A New generation of N-Aryl-N'-(1-alkyl-2-chloroethyl)ureas as microtubule disrupters: synthesis, antiproliferative activity, and β-tubulin alkylation kinetics. J. Med. Chem. 2003, 46(23), 5055-5063.
50. Petitclerc, E.; Deschesnes, R.G.; Cõté, M.F.; Marquis, C.; Janvier, R.; Lacroix, J.; Miot-Noirault, E.; Legault, J.; Mounetou, E.; Madelmont, J.-C.; C.-Gaudreault, R. Antiangiogenic and antitumoral activity of phenyl-3-(2-Chloroethyl)ureas: a class of soft alkylating agents disrupting microtubules that are unaffected by cell adhesion-mediated drug resistance. Cancer Res. 2004, 64(13), 4654-4663.
51. Fortin, J.S.; Lacroix, J.; Desjardins, M.; Patenaude, A.; Petitclerc, E.; Gaudreault, R.C. Alkylation potency and protein specificity of aromatic urea derivatives and bioisosteres as potential irreversible antagonists of the colchicine-binding site. Bioorg. Med. Chem. 2007, 15(13), 4456-4469.
52. Ravelli, R.B.G.; Gigant, B.; Curmi, P.A.; Jourdain, I.; Lachkar, S.; Sobel, A.; Knossow, M. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 2004, 428(6979), 198-202.
53. Tao, Z.-F.; Wang, L.; Stewart, K.D.; Chen, Z.; Gu, W.; Bui, M.; Merta, P.; Zhang, H.; Kovar, P.; Johnson, E.; Park, C.; Judge, R.; Rosenberg, S.; Sowin, T.; Lin, N.H. Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors. J. Med. Chem. 2007, 50(7), 1514-1527.
54. Tao, Z.F.; Lin, N.H.; Wang, L.; Sowin, T.J. Macrocyclic kinase inhibitors. U.S. Patent 20050215556, 2005.
55. Tao, Z.F.; Lin, N.H.; Wang, L.; Sowin, T.J.; Sullivan, G.M.; Tong, Y.; Przytulinska, M.; Li, G. Macrocyclic kinase inhibitors. W.O. Patent 2005047294, 2005.
56. 2 cell cycle checkpoints. Cancer Res. 2003, 63(2), 31-35.
57. Eastman, A.; Kohn, E.A.; Brown, M.K.; Rothman, J.; Livingstone, M.; Blank, D.H.; Gribble, G.W. A novel indolocarbazole, ICP-1, abrogates DNA damage-induced cell cycle arrest and enhances cytotoxicity: similarities and differences to the cell cycle checkpoint abrogator UCN-01. Mol. Cancer Ther. 2002, 1(12), 1067-1078.
58. Jackson, J.R.; Gilmartin, A.; Imburgia, C.; Winkler, J.D.; Marshall, L.A.; Roshak, A. An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage. Cancer Res. 2000, 60(3), 566-572.
59. Li, G.Q.; Tao, Z.F.; Tong, Y.S.; Przytulinka, M.K.; Koar, P.; Merta, p.; Chen, Z.H.; Zhang, H.; Sowin, T.; Rosenberg, S.H.; Lin, N.H. Synthesis and in-vitro biological activity of macrocyclic urea Chk1 inhibitors. Bioorg. Med. Chem. Lett. 2007, 17(23), 6499-6504.
60. Tao, Z.F.; Chen, Z.H.; Bui, M.H.; Koar, P.; Johnson, E.; Bouska, J.; Zhang, H.; Sowin, T.; Rosenberg, S.H.; Lin, N.H. Macrocyclic ureas as potent and selective Chk1 inhibitors: An improved synthesis, kinome profiling, structure-activity relationships, and preliminary pharmacokinetics. Bioorg. Med. Chem. Lett. 2007, 17(23), 6593-6601.
61. Carmeliet, P.; Jain, R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407(6801), 249-257.
62. Zetter, B.R. Angiogenesis ischemic and neoplastic disorders. Annu. Rev. Med. 1998, 49(2), 407-424.
63. Ferrara, N.; Kerbel, R.S. Angiogenesis as a therapeutic target. Nature 2005, 438(7070), 967-974.
64. Ullrich, A.; Schlessinger, J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990, 61(2), 203-212.
65. Hubbard, S.R.; Till, J.H. Protein tyrosine kinase structure and function. Rev. Biochem. 2000, 69(3), 373-398.
66. Yancopoulos, G.D.; Davis, S.; Gale, N. W.; Rudge, J.S.; Wiegand, S.J.; Holash, J. Regulation of hypoxia-induced angiogenesis: a chaperone escorts VEGF to the dance. Nature 2000, 407(6801), 242-248.
67. Bilodeau, M.T.; Fraley, M.E., Hartman, G.D. Kinase insert domain-containing receptor kinase inhibitors as anti-angiogenic agents. Expert Opin. Invest. Drugs 2002, 11 (6), 737-745.
68. Dai, Y.; Guo, Y.; Frey, R. R.; Ji, Z.; Curtin, M.L.; Ahmed, A.A.; Albert, D.H.; Arnold, L.; Arries, S.S.; Barlozzari, T.; Bauch, J.L.; Bouska, J.J.; Bousquet, P.F.; Cunha, G.A.; Glaser, K.B.; Guo, J.; Li, J.; Marcotte, P.A.; Marsh, K.C.; Moskey, M.D.; Pease, L.J.; Stewart, K.D.; Stoll, V.S.; Tapang, P.; Wishart, N.; Davidsen, S.K.; Michaelides, M.R. Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. J. Med. Chem. 2005, 48(19), 6066-6083.
69. Dai, Y.; Hartandi, K.; Ji, Z.; Ahmed, A.A.; Albert, D.H.; Arnold, L.; Arries, S. S.; Barlozzari, T.; Bauch, J.L.; Bouska, J.J.; Bousquet, P.F.; Cunha, G.A.; Glaser, K.B.; Guo, J.; Li, J.; Marcotte, P.A.; Marsh, K.C.; Moskey, M.D.; Pease, L.J.; Stewart, K.D.; Stoll, V.S.; Tapang, P.; Wishart, N.; Davidsen, S.K.; Michaelides, M.R. Discovery of N-(4-(3-amino-1H-indazol-4- yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor. J. Med. Chem. 2007, 50(7), 1584-1597.
70. Song, E.Y.; Kaur, N.; Park, M.Y.; Jin, Y.; Lee, K.; Kim, G.; Lee, K.Y.; Yang, J.S.; Shin, J.H.; Nam, K.Y.; No, K.T.; Han, G. Synthesis of amide and urea derivatives of benzothiazole as Raf-1 inhibitor. Eur. J. Med. Chem. 2008, 43(4), 1519-1524.
71. Li, H.Q.; Zhu, T.T.; Yan, T.; Luo, Y.; Zhu, H.L. Design, synthesis and structure-activity relationships of antiproliferative 1,3-disubstituted urea derivatives. Eur. J. Med. Chem. 2009, 44(3), 453-459.
72. Mol, C.D.; Dougan, D.R.; Schneider, T.R.; Skene, R.J.; Kraus, M.L.; Scheibe, D.N.; Snell, G.P.; Zou, H.; Sang, B.-C.; Wilson, K.P. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J. Biol. Chem. 2004, 279(30), 31655-31663.
73. Miyazaki, Y.; Matsungaga, S.; Tang, J.; Maeda, Y.; Nakano, M.; Philippe, R.J.; Shibahara, M.; Liu, W.; Sato, H.; Wang, L.; Nolte, R.T. Novel 4-amino-furo[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual inhibitors. Bioorg. Med. Chem. Lett. 2005, 15(9), 2203-2207.
74. Dumas, J.; Smith, R.A.; Lowinger, T.B. Protein kinase inhibitors from the urea class. Curr. Opin. Drug Discov. Dev. 2002, 5(5), 718-727.
75. Daniel, H.A.; Tapang, P.; Magoc, T.J.; Pease, L.J.; Reuter, D.R.; Wei, R.-Q.; Li, J.; Guo, J.; Bousquet, P.F.; Ghoreish-Haack, N.S.; Wang, B.; Bukofzer, G.T.; Wang, Y-C.; Stavropoulos, J.A.; Hartandi, K.; Niquette, A.L.; Soni, N.; Johnson, E.F.; McCall, J.O.; Bouska, J.J.; Luo, Y.; Donawho, C.K.; Dai, Y.; Marcotte, P.A.; Glaser, K.B.; Michaelides, M.R.; Davidsen, S.K. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Preclinical Mol. Cancer Ther. 2006, 5(4), 995-1006.
76. Ullrich, A.; Schlessinger, J. Singnal transduction by receptors with tyrosine kinase activity. Cell 1990, 61(2), 203-212.
77. Hubbard, S.R.; Till, J.H. Protein tyrosine kinase structure and function. Annu. Rev. Biochem. 2000, 69(3), 373-398.
78. Hayman, M.J.; Enrietto, P.J. Cell transformation by the epidermal growth factor receptor and v-erbB. Cancer Cells 1991, 3(3), 302-307.
79. Dikic, I.; Giordano, S. Negative receptor signalling. Curr. Opin. Cell Biol. 2003, 15(2), 128-135.
80. Uckun, F.M.; Mao, C. Structure-based design of novel anticancer agents. Curr. Pharm. Des. 2004, 10(10), 1083-1091
81. Traxler, P.; Green, J.; Mett, H.; Sequin, U.; Furet, P. Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: isoflavones and 3-Phenyl-4(1H)-quinolones J. Med. Chem. 1999, 42(6), 1018-1026.
82. Cao, P.; Huang, X.F.; Ding, H.; Ge, H.M.; Li, H.Q.; Ruan, B.F.; Zhu, H.L. Synthesis and evaluation of urea derivatives as inhibitors of human leukemic K562 cell line. Chem. Biodivers. 2007, 4(5), 881-886.
83. Shao, L.; Zhou, X.; Jin, Z.; Fang, J.X. Synthesis, structure, and biological activity of novel 4,5-disubstituted thiazolyl urea derivatives. Hereroatom. Chem. 2008, 19(6), 2-6.
84. Paolo, P.; Raffaella, A.; Gabriella, T., Manuela, A.; Anna, V.; Antonella, I. 2-ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents. WO Patent 2000026203, 2000.
85. Ehlhardt, W.J.; Woodland, J.M.; Toth, J.E.; Ray, J.E.; Martin, D.L. Disposition and metabolism of the sulfonylurea oncolytic agent LY295501 in mouse, rat, and monkey. Drug Metab. Dispos. 1997, 25(6), 701-708.
86. Gil, M.J.; Mañú, M.A.; Arteaga, C.; Migliaccio, M.; Encío, I.; González, A.; Martínez-Merino, V. Synthesis and cytotoxic activity of N-(2-pyridylsulfenyl)urea derivatives: A new class of potential antineoplastic agents. Bioorg. Med. Chem. Lett. 1999, 9(16), 2321-2324.
87. Robinson,M.J.; Cobb, M.H. Mitogen-activated protein kinase pathways. Curr. Opin. Cell Biol. 1997, 9(2), 180-186.
88. Bos, J.L. Ras oncogenes in human cancer: a review. Cancer Res. 1989, 49(17), 4682-4689.
89. Malumbres, M.; Barbacid, M. RAS oncogenes: the first 30 years. Nat. Rev. Cancer 2003, 3(6), 459-465.
90. Lyons, J.F.; Wilhelm, S.; Hibner, B.; Bollag, G.; Discovery of a novel Raf kinase inhibitor. Endocr. Relat. Cancer 2001, 8(3), 219-225.
91. Yamazaki, K.; Kaneko, Y.; Suwa, K.; Ebara, S.; Nakazawa, K.; Yasuno, K. Synthesis of potent and selective inhibitors of Candida albicans N-myristoyltransferase based on the benzothiazole structure. Bioorg. Med. Chem. 2005, 13(7), 2509-2522.
92. Brantley, E.; Antony, S.; Kohlhagen, G.; Meng, L.H.; Agama, K.; Stinson, S.F.; Sausville, E.A.; Pommier, Y. Antitumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces single-strand breaks and DNA-protein cross-links in sensitive MCF-7 breast cancer cells. Cancer Chemother. Pharmacol. 2006, 58(1), 62-72.
93. Lion, C.J.; Matthews, C.S.; Wells, G.; Bradshaw, T.D.; Stevens, M.; Westwell, A.D. Antitumour properties of fluorinated benzothiazole-substituted hydroxycyclohexa-2,5-dienones ('quinols'). Bioorg. Med. Chem. Lett. 2006, 16(19), 5005-5008.
94. Huang, S.-T.; Hsei, I.-J.; Chena, C. Synthesis and anticancer evaluation of bis(benzimidazoles),bis(benzoxazoles), and benzothiazoles. Bioorg. Med. Chem. 2006, 14(17), 6106-6119.
95. McCann, S.M. Remembrance: the discovery of growth hormone (GH)-releasing hormone and GH release-inhibiting hormone. Endocrinology 1992, 131(5), 2042-2044.
96. Reisine, T. Somatostatin receptors. Am. J. Physiol. 1995, 269(6), 813-820.
97. Keri, G.; Mezo, I.; Vadasz, Z.; Horvath, A.; Idei, M.; Vantus, T.; Balogh, A.; Bokonyi, G.; Bajor, T.; Teplan, I.; Tamas, J.; Mak, M.; Horvath, J.; Structure-activity relationship studies of novel somatostatin analogs with antitumor activity. Pept. Res. 1993, 10(6), 281-288.
98. Brazeau, P.; Vale, W.; Burgus, R.; Ling, N.; Butcher, M.; Rivier, J.; Guillemin, R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973, 179(4068), 77-79.
99. Reubi, J.C. Evidence for two somatostatin-14 receptor types in rat brain cortex. Neurosci. Lett. 1984, 49(3), 259-263.
100. Liu, S.; Crider, A.M.; Tang, C.; Ho, B.; Ankersen, M.; Stidsen, C.E. Nonpeptide somatostatin agonists with sst4 selectivity: synthesis and structure-activity relationships of thioureas. J. Med. Chem. 1998, 41(23), 4693-4705.
101. Porcu, M.; Chiarugi, A. The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension. Pharmacol. Sci. 2005, 26(2), 94-103.
102. Milne, J.C.; Denu, J.M. The Sirtuin family: therapeutic targets to treat diseases of aging. Curr. Opin. Chem. Biol. 2008, 12(1), 11-17.
103. Neugebauer, R.C.; Sippl, W.; Jung, M. Inhibitors of NAD(+) dependent histone deacetylases (Sirtuins). Curr. Pharm. Des. 2008, 14(6), 562-573.
104. Napper, A.D.; Hixon, J.; McDonagh, T.; Keavey, K.; Pons, J.F.; Barker, J.; Yau, W.T.; Amouzegh, P.; Flegg, A.; Hamelin, E.; Thomas, R.J.; Kates, M.; Jones, S.; Navia, M.A.; Saunders, J.O.; DiStefano, P.S.; Curtis, R. Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J. Med. Chem. 2005, 48(25), 8045-8054.
105. Huhtiniemi, T.; Suuronen, T.; Rinne, V.M.; Wittekindt, C.; Lahtela-Kakkonen, M.; Jarho, E.; Wallen, E.A.A.; Salminen, A.; Poso, A.; Leppänen, J. Oxadiazole-carbonylaminothioureas as SIRT1 and SIRT2 inhibitors. J. Med. Chem. 2008, 51(15), 4377-4380.
106. Furuta, T.; Sakai, T.; Senga, T.; Osawa, T.; Kubo, K.; Shimizu, T.; Suzuki, R.; Yoshino, T.; Endo, M.; Miwa, A. Identification of potent and selective inhibitors of PDGF receptor autophosphorylation. J. Med. Chem. 2006, 47(8), 2186-2192.
107. Szallasi, A.; Blumberg, P.M. Vanilloid (Capsaicin) receptors and mechanisms. Pharmacol. Rev. 1999, 51(2), 159-212.
108. Appendino, G.; Szallasi, A. Euphorbium: modern research on its active principle, resiniferatoxin, revives an ancient medicine. Life Sci. 1997, 60(10), 681-696.
109. Caterina, M.J.; Schumacher, M.A.; Tominaga, M.; Rosen, T.A.; Levine, J.D.; Julius, D. The capsaicin receptor:a heat-activated ion channel in the pain pathway. Nature 1997, 389(6653), 816-824.
110. Lee, J.; Lee, J.; Kang, M.; Shin, M.; Kim, J.M.; Kang, S.U.; Lim, J.O.; Choi, H.K.; Suh, Y.G.; Park, H.G. N-(3-Acyloxy-2-benzylpropyl)-N¢-[4- (methylsulfonylamino)benzyl]thioure-a analogues: novel potent and high affinity antagonists and partial antagonists of the vanilloid receptor J. Med. Chem. 2003, 46(14), 3116-3126.